Author: Beghou Consulting

Read the latest news from Beghou Consulting, as well as our experts’ views on trends and challenges in the life sciences industry.

Dan Schulman addresses key considerations in orphan drug commercialization

Orphan drugs are different than mass-market therapies — and so is their commercial strategy. Orphan drug manufacturers should engage patients throughout research, development and commercialization — and hire specialized sales forces market the therapy to the most relevant physicians. Associate Partner Dan Schulman describes in Med Ad News the steps orphan drug manufacturers can take to ensure their life-saving treatments reach patients as quickly as possible.
Read More »

Esin Izat and Rob Lien on navigating the patient journey to inform commercial operations

An orphan drug manufacturer should follow the patient journey to account for various scenarios in the product’s forecast — from delays in therapy starts to patient compliance and retention. Associate Partner Rob Lien and Manager Esin Izat describe in Pharmaceutical Commerce how detailed analysis and marketing research can help life sciences companies overcome these challenges and contribute to commercial success.
Read More »

Dan Wetherill and Janardhan Vellore on how to “get ahead of scripts”

A life sciences company needs to rely on more than historical prescription volume to ensure product success in today’s hypercompetitive marketplace. Partner Dan Wetherill and Vice President Janardhan Vellore describe in Pharmaceutical Executive how life sciences companies can proactively increase the breadth and depth of prescriptions to propel brand performance.
Read More »